Abstract. NStearoyltyrosine (NsTyr), a synthesized anandamide (AEA) analogue, could exert potent neuroprotective effects on cerebral ischemia models both in vivo and in vitro via intervening in multiple injuries. Glutamate, a major excitatory neurotransmitter, plays a critical role during stroke/cerebral ischemia. In this study, we explored the protective effects of NsTyr on glutamate neurotoxicity in PC12 cells and investigated its underlying mechanisms. NsTyr treatment attenuated glutamateinduced oxidative toxicity in a dosedependent manner and the best perfor mance was observed at 10 mΜ. NsTyr treatment suppressed glutamate-induced upregulation of lipoxygenase 12/15 (LOX 12/15) activity and reactive oxygen species (ROS) elevation, attenuated the increase of BH3interacting domain death agonist (Bid) in the mitochondria, prevented the loss of mitochondria membrane potential and consequently inhibited apoptosisinducing factor (AIF) translocation into the nucleus. The results demonstrated that NsTyr could protect cells against AIFmediated caspaseindependent cell death induced by glutamate, which may be due to the blockage of Bidmediated mitochondrial damage via reducing LOX 12/15 activity and ROS accumulation.
Introduction
Stroke/cerebral ischemia, the second leading cause of mortality in the world, involves complex pathophysio logical processes (1) . Disturbance of glutamate levels is the primary cause of neuronal death in stroke/cerebral ischemia through excitotoxicity triggered by the over activation of glutamate ionotropic receptors and oxida tive toxicity initiated by the blockade of the cysteine/ glutamate antiporter (2) . The oxidative toxicity is an important component of glutamate neurotoxicity during cerebral ischemia (3) .
The pharmaceutical approaches intervening in multiple injuries instead of a single injury may function effec tively for multifaceted neuronal death in stroke/cerebral ischemia patients (4, 5) . Endocannabinoid anandamide (AEA) has been reported to protect neurons from ischemic injury via intervening in multiple injuries (6 -8) . However, AEA with a short metabolic halflife in vivo could not satisfy the requirements in clinical practice (9) . Developing novel AEA analogues without the abovementioned defect would be an alternation for neuroprotection. We have synthesized diverse Nfattyacyl amino acids as AEA analogues and evaluated their neuroprotective effects. One of them, Nstearoyltyrosine (NsTyr, Fig. 1 ), showed potent activities on stroke/cerebral ischemia models and is a promising neuroprotective candidate currently in preclinical studies in China. The underlying mechanisms of NsTyr were proved to intervene in multiple injuries, such as antagonizing against OGD induced neuronal injury, inhibiting the inflammatory response, and regulating neuronal plasticity (10 -12) . Glutamate neurotoxicity plays an important role in neuronal death under stroke/cerebral ischemia conditions (2) . In the present study, we verified that NsTyr exerts its neuroprotective effects by acting on glutamate toxicity in PC12 cells. Its neuroprotective effects on glutamateinduced oxidative toxicity are exerted at least partially through the blockage of the apoptosisinducing factor (AIF)mediated caspaseindependent cell death pathway.
Materials and Methods
Reagents DMEM medium, fetal bovine serum (FBS), glutamine, penicillin, streptomycin, and JC1 assay kit were pur chased from Gibco Invitrogen (Carlsbad, CA, USA). Annexin VFITC apoptosis detection kit, TUNEL (tdT mediated dUTP nickend labeling) assay kit, and ROS assay kit were purchased from Becton Dickinson Company (San Jose, CA, USA). 3(4,5Dimethylthiazol 2yl)2,5diphenyl tetrazolium bromide (MTT), MK 801, CNQX, NAC, zVADFMK, BI6C9, baicalein, nuclear extraction kit, and mitochondria extraction kit were obtained from Sigma Chemical Co. (St. Louis, MO, USA). All antibodies were obtained from Santa Cruz Biotechnology (Santa Cruz, CA, USA) unless specified in the text. The other chemicals and reagents were ana lytical grade and were purchased from local commercial suppliers.
Synthesis of NsTyr
NsTyr used in the study was synthesized in our labora tory as described (10) . Briefly, a mixture of 9 g N,N′-dicyclohexylcarbodiimide (43.6 mmol), 10 g stearic acid (35.2 mmol), 6 g Nhydroxysuccinimide (52.1 mmol), and 80 ml tetrahydrofuran (THF) were placed in an icebath with stirring for 16 h to provide stearic acid 2,5dioxopyrrolidin1yl ester. After filtration, evapora tion, and recrystallization in isopropanol, the Nhydroxy succinimide ester of stearic acid was obtained with a yield 90%. Then 5 mmol Nhydroxysuccinimide ester of stearic acid in 20 ml THF was added dropwise to a 20ml aqueous solution of 5.5 mmol ltyrosine and 15 mmol NaHCO 3 . The mixture was stirred for 6 h at room temperature. The solvent was removed under reduced pressure. The residue was dissolved in water and adjusted with 1 M HCl to pH 3, and the solution was extracted with ethyl acetate (2 times × 50 ml). The combined organic extracts were successively washed with water and saturated NaCl solution and then dried over anhydrous sodium sulfate and evaporated to dryness. The structure of NsTyr was confirmed by the physical constants and spectral data ( 1 H NMR and 13 C NMR) (10) . Its DMSO stock solution (10 mM) was stored at −80°C.
Cell culture and drug treatment
PC12 cells were obtained from the Chinese Academy of Sciences (Shanghai, China). Cells were cultured in DMEM supplemented with 10% FBS, 2 mM glutamine, 100 U/ml penicillin, and 10 mg/ml streptomycin at 37°C in a humidified atmosphere of 95% air and 5% CO 2 . The cells were plated at an appropriate density according to each experimental scale and NsTyr, MK801 (5 mM), CNQX (20 mM), NAC (5 mM), and zVADFMK were added 1 h before addition of glutamate. All inhibitors were freshly constituted in DMSO.
Cell viability assay
Cell survival was evaluated with the MTT assay. Briefly, PC12 cells were seeded into 96well plates at 2 × 10 4 cells per well and maintained in a CO 2 incubator at 37°C overnight. After 24 h glutamate treatment, MTT was added to each well at final concentration of 1 mg/ml. After additional incubation of 4 h at 37°C, the supernatants were removed, and 100 ml of DMSO was added to dissolve the insoluble dark blue formazan crystals. The absorbance was measured at 570 nm with a reference wavelength of 630 nm using a microtiter plate reader (Quant; BioTek Instruments Inc., Winooski, VT, USA).
Flow cytometry
After glutamate treatment with or without NsTyr, PC12 cells were doublelabeled with Annexin VFITC and propidium iodide (PI) using an Annexin VFITC Apoptosis Detection Kit for flow cytometry (FCM) analysis. Briefly, after the indicated treatment, the cells were washed with PBS, dissociated with 0.25% trypsin EDTA, and resuspended in 1 ml Annexin V binding buffer (10 mM HEPES, 140 mM NaCl, 2.5 mM CaCl 2 , pH 7.4). Cells (2 × 10 5 ) were stained with 5 ml Annexin VFITC and 0.5 mg/ml PI in 100 ml binding buffer at 4°C, according to manufacturer's instructions. Samples were incubated in the dark at room temperature for 15 min. Subsequently, 400 ml binding buffer was added, and samples were analyzed using a trilaser FACSCalibur flow cytometer (Becton Dickinson, San Jose, CA, USA). The fluorescence intensities of Annexin VFITC and PI were measured at fluorescence channels 1 and 3, respec tively. Annexin VFITC-positive and PInegative cells are apoptotic, both positive necrotic, and both negative live.
Mitochondrial membrane potential assay
Mitochondrial membrane potential (MMP) was evalu ated by JC-1 reduction according to the manufacturer's instructions. After glutamate treatment 12 h with or without NsTyr, PC12 cells were washed by PBS, incubated in 2.5 mM JC-1 at 37°C for 30 min, and then washed with DMEM three times. The fluorescence was captured by a Zeiss 510 laser scanning confocal micro scope (Munchen, Bayern, Germany).
Measurement of reactive oxygen species
Reactive oxygen species (ROS) production was determined using 2′,7′-dichloro-fluorescein diacetate (H2DCFDA). After treatment with or without NsTyr for 1 h, the cells exposed to glutamate for 8 h. Then the culture medium was removed, and the cells were washed gently with HBSS 3 times. H2DCFDA stock solution was diluted to 10 mM with cell culture medium without FBS. The 10 mM H2DCFDA was added to the cells and incubated for 10 min at 37°C and then the cells were washed with warmed phenol red-free DMEM 3 times. Accumulation of the intracellular ROS was observed and photographed under a Zeiss 510 laser scanning confocal microscope with the appropriate fluorescence filters (excitation wavelength of 488 nm and emission wave length of 525 nm). To avoid photooxidation of fluores cence, the images were collected using a single rapid scan, and identical settings were used for all samples. Fluorescence images were quantified with NIH Image J analysis software and evaluated by comparing with the control.
Electron microscopy
After glutamate treatment with or without NsTyr for 15 h, cells were collected by trypsinisation, washed once in PBS, and fixed for 30 min in 3% glutaraldehyde in 0.1 M phosphate buffer (pH 7.4). After removal of glutaraldehyde, cells were embedded in 2% w/v agar in PBS and postfixed in OsO 4 for 15 min at 4°C. Samples were dehydrated in acetone and embedded in SPURR resin. Ultrathin sections (70 -90 mm) were cut with an UltracutE ultratome (ReichertJung, Vienna, Austria). Photographs were taken using a Philip CM120 trans mission electron microscope CM120 (Eindhoven, Netherlands).
Immunocytochemistry
After glutamate treatment with or without NsTyr for 15 h, PC12 cells were fixed with 4% PFA for 20 min at room temperature and then blocked and permeabilized with PBS containing 10% goat serum and 0.1% Triton X100 for 1 h at room temperature. Following incubation with monoclonal antiAIF antibody (1:100 in blocking solution) at 4°C overnight, the cells were exposed to the FITCcoupled goat antimouse secondary antibody (1:400) at room temperature for 1 h. The specificity of AIF immunoreactivity was captured by the Zeiss 510 laser scanning confocal microscope with the appro priate fluorescence filters (excitation wavelength of 488 nm and emission wavelength of 525 nm).
Cytoplasmic and nuclear protein extraction
PC12 cells were incubated with or without 10 mM glutamate and/or 10 mΜ NsTyr for 15 h. The cytoplasmic fraction and the nuclei were isolated with a nuclear extraction kit according to the manufacturer's instruc tions. Cytoplasmic and nuclear protein concentration was determined by the Thermo BCA protein assay (Pierce, Rockford, IL, USA). Samples of 10 mg cyto plasmic or nuclear proteins were used for western blot analysis.
Mitochondria isolation
After treatment with or without 10 mM glutamate and/or 10 mΜ NsTyr for 12 h, PC12 cells were harvested from 10cm dishes and centrifuged at 700 × g for 2 min. Then, the supernatants were removed and the mito chondria were prepared. Mitochondrial proteins were extracted by a mitochondria extraction kit according to the manufacturer's instructions. Samples of 5 mg mito chondrial proteins were used for western blot analysis.
Western blot analysis
After treatment, PC12 cells were rinsed with PBS and lysed with an icecold lysis buffer and then centrifuged at 15,000 × g for 15 min at 4°C. The supernatants were collected, and the protein concentration was evaluated with the Thermo BCA protein assay. Proteins from cell lysates were denatured at 99°C for 10 min and 35 mg proteins were separated on a 10% SDS-polyacrylamide gel and electrotransferred to a nitrocellulose membrane. Membranes were blocked with 5% nonfat milk in Tris buffered saline-0.1% Tween 20 (TBST) for 1 h. After incubation overnight at 4°C with monoclonal mouse antiAIF antibody, polyclonal rabbit antiBid antibody (1:200), monoclonal rabbit antiGAPDH antibody (1:1000), and polyclonal rabbit antiLOX 12/15 (1:1000 dilution; Cayman Chemical, Ann Arbor, MI, USA), the membranes were washed and then incubated with secondary antibody, antirabbit or antimouse IgG HRP linked antibody (1:2000) , for 1 h. Proteins were visual ized by an enhanced chemiluminescense detection kit (Pierce). The optical density of each band was quantified using image analysis software (Quantity One v4.4.0, BioRad).
15-HETE measurement
The lipoxygenase 12/15 (LOX 12/15) activity was measured by determining the levels of its metabolite 15hydroxyeicosatetraenoic acid (15HETE). Cells (2 × 10 6 ) seeded on a 6cm 2 dish. After exposure to glutamate for 8 h with or without NsTyr, 15HETE concentrations were measured with the 15(S)HETE Enzyme Immunoassay kit (Assay Designs, Ann Arbor, MI, USA), in accordance with the manufacturer's instructions.
Statistical analyses
All values were expressed as means ± S.E.M. Com parisons among multiple groups involved oneway ANOVA followed by the Student-Newman-Keuls test and Dunnett's test (for comparison of multiple experi mental treatments to a common control value). In all experiments, differences were considered to be statisti cally significant at P < 0.05. Generally, the Pvalue means the comparison with the glutamatetreated group unless indicated otherwise.
Results

Glutamate-induced PC12 cell death was due to nonreceptor-mediated oxidative toxicity through a caspaseindependent pathway
After the treatment with 10 mM glutamate for 24 h, the viability of PC12 cells evaluated by MTT assay was reduced to about 25% of that in the control group (P < 0.001) (Fig. 2A) . To understand the mechanisms of the glutamateinduced PC12 cell death, the antioxidant (5 mM NAC), caspase inhibitor (10 -30 mM zVAZ FMK), and glutamate receptor antagonists (5 mM MK801 and 20 mM CNQX) were applied, respectively, 1 h prior to the treatment of glutamate. Only NAC resulted in a significant enhancement of cell viability (P < 0.001) in the presence of glutamate, while zVAZ FMK, MK801, and CNQX (Fig. 2B ) each showed no obvious effect (P > 0.05), suggesting that glutamate induced PC12 cell death was mainly due to nonreceptormediated oxidative toxicity through a caspaseindepen dent pathway.
NsTyr treatment resulted in the protective effects on glutamate-induced cell death
The protective effects of NsTyr on glutamate neuro toxicity were observed in PC12 cells. NsTyr at 1 -10 mM did not affect the viability of PC12 cells for the control group, but reduced glutamateinduced cell death in a concentration and timedependent manner (Fig. 3:  A, B) . Pretreatment with 10 mM NsTyr for 1 h almost completely protected the PC12 cells against glutamate induced cell death (P < 0.001), which was consistent Fig. 2 . Glutamateinduced neurotoxicity in PC12 cells was nonreceptor-mediated oxidative toxicity through a caspase independent cell death pathway. PC12 cells were pretreated with receptor antagonists (5 mM MK801 or 20 mM CNQX), anti oxidant (5 mM NAC) (A), and caspase inhibitor (zVADFMK) (B) for 1 h, followed by exposure to 10 mM glutamate for 24 h, and then cell viability was determined by MTT assay. Results were expressed as a percentage of the control group. Data were expressed as the mean ± S.E.M. of 3 independent experiments. ***P < 0.001 vs. GLU.
with the observations by microscopy and flow cytometry (Fig. 3: C, D) .
NsTyr inhibited glutamate-induced AIF nuclear translocation
In glutamateinduced caspaseindependent cell death, translocation of AIF into the nucleus led to largescale DNA fragmentation (> 50 kbp) and subsequent cell death (13) . Blockage of the AIF nuclear translocation could resist glutamateinduced cell death (14) . Therefore, we were interested in the relationship of neuroprotective effects of NsTyr and AIF nuclear translocation. NsTyr alone had no obvious effects on AIF levels in the nucleus, cytoplasm, and mitochondria of PC12 cells. As illus trated in Fig. 4A , glutamate treatment upregulated the AIF levels in the nucleus and cytoplasm and down regulated the AIF levels in mitochondria (P < 0.01), while NsTyr treatment significantly reversed the gluta mate effects. Taken together, NsTyr treatment signifi cantly prevented the glutamateinduced AIF release and nuclear translocation, which was also confirmed by observation with confocal microscopy (Fig. 4B) . Fig. 3 . Neuroprotective effects of NsTyr on glutamateinduced oxidative toxicity. After preincubation with certain does of NsTyr for 1 h, PC12 cells were exposed to 10 mM glutamate for 24 h. A) Cell viability was detected by MTT assay. B) 10 mM NsTyr was added to the culture media 1 h before glutamate treatment, simultaneously with glutamate treatment, at 1 and 2 h after glutamate treatment. Cell viability was determined with MTT assay. C) After treatment with 10 mM NsTyr for 1 h, followed by exposure to 10 mM glutamate, cell morphologies were observed and photographed with a phasecontrast microscope. Scale bar, 40 mm. D) PC12 cells were stained with Annexin V and PI, and the frequency of Annexin V and PIpositive labeling was recorded by flow cytometry and illustrated as a plot.
NsTyr blocked the Bid-mediated mitochondrial damage induced by glutamate
Mitochondrial damage is an essential earlier event for AIF nuclear translocation and cell death (13, 15) , and the depletion of MMP is an important early determinant for the mitochondrial damage (16) . As shown in Fig. 5A , glutamate treatment for 12 h caused a significant loss of JC1 red fluorescence, indicating the loss of MMP, whereas NsTyr treatment almost completely abrogated the MMP reduction. In addition, observation under the transmission electron microscopy (Fig. 5B) showed most mitochondria of cells after glutamate treatment for 15 h were swollen and some of them even lost cristae, whereas NsTyr treatment reversed the morphological alterations. These data suggested that NsTyr prevented glutamate induced mitochondrial damage.
Bid, a proapoptosis Bcl2 family protein, can be activated in response to glutamate toxicity and insert into the outer mitochondrial membrane, resulting in mitochondrial damage and cell death (17) . Bid inhibitor BI6C9 (20 mM) reversed glutamateinduced PC12 cell death (Fig. 5C ) and the glutamate treatment did not alter the total Bid expression, but elevated Bid levels in the mitochondria almost doubly, and NsTyr reduced Fig. 4 . NsTyr inhibited glutamateinduced AIF nuclear translocation. PC12 cells were pretreated with or without NsTyr for 1 h and then exposed to glutamate for 15 h. A) The nuclear, cytoplasmic, and mitochondrial protein were determined by western blot analysis. Lamin A, GAPDH, and COX IV served as the loading control for nuclear, cytoplasmic, and mitochondrial protein respectively. Values of densitometric analysis were means ± S.E.M. of 3 independent experiments. **P < 0.01, *P < 0.05 vs. GLU. Scale bar, 20 mm. B) Cells were fixed and immunostained for AIF (green) and nucleus (blue). Pictures were taken with a confocal microscope. Twenty microscopic fields per culture were evaluated in a blind manner. The results shown are representa tive of those from at least 3 different experiments.
the mitochondrial Bid levels to normal levels (Fig. 5D) . Taken together, those results suggested that NsTyr prevented glutamateinduced Bidmediated mitochon drial damage.
NsTyr could reduce glutamate-induced ROS accumulation via inhibiting LOX 12/15 activity
Excessive glutamate could result in the accumulation of ROS, which further elicited Bidmediated mitochon drial damage (15) . Using H2DCFDA, a fluorescent dye, we observed that the intracellular ROS increased significantly in the PC12 cells treated with glutamate for 8 h compared with untreated cells (P < 0.001, Fig. 6A ), while NsTyr reduced the increase of ROS levels (P < 0.001).
The inhibition of LOX 12/15, one of the key mediators NsTyr and then exposed to 10 mM glutamate. A) After exposure to glutamate for 12 h, MMP was measured using JC1: the upper panels (red fluorescence) depict intact mitochondria, and the lower panels (green fluorescence) indicated equal cellular uptake of JC1. Scale bar, 20 mm. B) After exposure to glutamate for 15 h, the morphologies of mitochondria were observed and photographed with an electron microscope. Scale bar, 1 mm. C) PC12 cells were pretreated with different doses of BI6C9, followed by exposure to 10 mM glutamate for 24 h, and then cell viability was determined by MTT assay. Results are expressed as a percentage of the control group. Data are expressed as the mean ± S.E.M. of 3 independent experiments. ***P < 0.001 vs. GLU. D) After exposure to glutamate for 12 h, mitochondrial and wholecell protein were prepared and analyzed by western blotting. COX IV and GAPDH were included as the loading control for mitochondrial and wholecell protein, respectively. Values of densitometric analysis were means ± S.E.M. of 3 independent experiments. **P < 0.01, *P < 0.05 vs. GLU.
in glutamateinduced oxidative toxicity, could alleviate ROS accumulation (18) . At 10 mΜ, baicalein, an LOX 12/15 inhibitor, reduced ROS accumulation and attenuated glutamateinduced PC12 cell death signifi cantly ( Fig. 6: A, B) . Treatment of glutamate for 8 h resulted in no significant effects on LOX 12/15 expres sion (Fig. 6C) . In contrast, the activity of 12/15LOX in the glutamate group, measured by levels of its metabo lite 15HETE, increased to about 2.3fold that of the control group, while 10 mM NsTyr treatment produced 48.1% reduction in LOX 12/15 activity (Fig. 6D) .
Discussion
Stroke/cerebral ischemia is a multifactorial patho physiologic process such as oxygen and glucose depriva tion (OGD), glutamate disturbance, and inflammation (1) . Agents with the potential to intervene in multiple injuries would offer a novel therapeutic strategy for stroke/cerebral ischemia (4, 5) . Endocannabinoid AEA can protect neurons from damages through intervening in multiple injuries, such as inhibiting glutamate release (19 -21) , scavengering free radicals (6, 22, 23) , reduc ing Ca 2+ influx (24, 25) , and decreasing inflammatory response (8) . However, it is difficult to use AEA in clinical practice because it is rapidly degraded (26) . Hence, developing novel AEA analogues with predomi nant pharmaceutical activity may offer an alternative candidate for stroke/cerebral ischemia therapy.
NsTyr, an AEA analogue developed in our laboratory, could remarkably decrease hippocampal neuron apopto sis and ameliorate learning and memory in the rats followed by acute or chronic cerebral ischemic injury (11, 12) . The mechanism study revealed that NsTyr protected neurons against OGD or LPS injury through reducing Ca 2+ influx, regulating expression of apoptosis associated genes, and decreasing the inflammation response (10), implicating NsTyr's neuroprotective effects are exerted by intervening in multiple injuries. The good pharmacokinetics of oral administration of NsTyr was also summarized by its metabolic halflife of 3 h and the presence in the brain at 8 h after NsTyr administration (data not shown). Although glutamate is one of vital pathophysiological factors in cerebral ischemic injury, the effects of NsTyr on glutamate neurotoxicity are unclear. To clarify NsTyr's neuroprotective activity through intervening in multiple inju ries, the present work investigates the effects of NsTyr on glutamateelicited cell injury and its underlying mechanisms. Excessive glutamate could decrease cystine uptake through interfering with the glutamate/cystine antiporter, resulting in intracellular GSH depletion, and finally in oxidative toxicity, which is a critical component of glutamate neurotoxicity during cerebral ischemia (27 -29) . In the present study, the protective effects of antioxidant rather than the glutamatereceptor antago nists against glutamateinduced PC12 cell death were observed, indicating that glutamate induces cellular injury mainly through oxidative toxicity. Treatment of PC12 cells with NsTyr significantly abated cell damage after glutamate exposure, showing NsTyr's abil ity to prominently protect cells from glutamateinduced oxidative toxicity.
Glutamateinduced oxidative injury can be mediated via the caspasedependent or caspaseindependent cell death pathway (14, 30) . The caspaseindependent AIF signaling is the main pathway (31, 32) through which glutamate induced cell death in immortalized HT22 hippocampal neurons (13) . In this study, inhibition of caspases did not block the PC12 cell damage triggered by glutamate (Fig. 2B ) and a significant increase of AIF in nucleus was observed after glutamate exposure (Fig. 4) , which might implicate that glutamateinduced damage in PC12 cells is mainly through the AIFrelated caspaseindependent pathway. Inhibiting AIF nuclear translocation or downregulating AIF levels would effectively antagonize OGD or glutamateinduced caspaseindependent apoptosis (13, 33) . We observed that the treatment with NsTyr could significantly reduce glutamateinduced AIF nuclear translocation in PC12 cells (Fig. 4) and inhibit the dramatic increase of the nuclear AIF in ischemic cerebral cortex and hippo campus of rats after middle cerebral artery occlusion (MCAO) (34) . The results suggested that NsTyr could exert neuro protective effects by blocking the AIFrelated caspaseindependent cell death pathway.
Mitochondria damage results in the release of pro apoptotic proteins such as cytochrome c and AIF, which trigger caspasedependent or caspaseindependent cell death (35) . Bid has been proved to play a pivotal role for mitochondrial damage in neuronal cell death (36, 37) . During glutamateinduced oxidative toxicity, ROS accumulation can activate fulllength Bid, which migrates to the mitochondrial membrane (38) , leading to the depletion of MMP and mitochondrial damage (15) . In this study, the Bid inhibitor BI6C9 completely abolished glutamate injury (Fig. 5C ), suggesting that Bidmediated mitochondria damage is involved in gluta mateinduced PC12 cell death (39) . NsTyr treatment re duced ROS formation (Fig. 6A) , reduced the fulllength Bid levels in the mitochondria (Fig. 5D) , and attenuated the mitochondrial damage (Fig. 5: A, B) , implicating that NsTyr might block Bidmediated mitochondrial damage through suppressing ROS elevation.
LOX 12/15, a principal lipoxygenase isoform in the CNS, plays a critical role in neuron death during gluta mate injury (18, 40) . The inhibition of LOX 12/15 could reduce the formation of ROS and lipid peroxidation and exert neuroprotective effects in vitro and in vivo (40 -42) . In this study, baicalein significantly sup pressed ROS accumulation and protected PC12 cells from glutamateinduced oxidative toxicity (Fig. 6: A, B) and NsTyr inhibited LOX 12/15 activity but did not influence the levels of LOX 12/15 ( Fig. 6: C, D) , sug gesting that LOX 12/15 is involved in the ROS accumu lation induced by glutamate and that NsTyr's effect on ROS was due to suppressing the activity of LOX 12/15. Moreover, our previous study showed that NsTyr could significantly increase the activities of antioxidative enzymes (43) , which may also contribute to the suppres sion of NsTyr's effects on ROS accumulation. Therefore, the suppression of NsTyr on ROS may be partially dependent on its inhibitory effect on LOX 12/15 activity.
Although NsTyr is an analog of AEA, no affinity of NsTyr with CB1 or CB2 receptor was observed (data not shown). Therefore, NsTyr should not be an agonist for CB receptors and NsTyr is an inhibitor of fatty acid amide hydrolase (FAAH) (IC50 < 1 mM), which is primarily responsible for the degradation of AEA. FAAH inhibitors have neuroprotective effects on several injuries (44 -47) , including the glutamatergicrelated ones (48). So we suggest that NsTyr may exert neuroprotection through inhibiting FAAH activity and then regulating endocannabinoid levels following glutamate stimuli.
Above all, this study showed for the first time that NsTyr could protect against glutamateinduced AIF mediated caspaseindependent cell death, which may be at least due to the inhibition of Bidmediated mitochon drial damage via reducing LOX 12/15 activity and ROS accumulation. In addition, our results strongly suggest that NsTyr exerts its neuroprotective effects by interven ing in multiple injuries and therefore would be a pro mising neuroprotective candidate for stroke/cerebral ischemia therapy.
